1 **ORIGINAL ARTICLE**

Development and Validation of Prediction Models for Sentinel 2

Lymph Node Status Indicating Postmastectomy Radiotherapy in 3

Breast Cancer: a Population-Based Study of 18 185 Women 4

- 5 Miriam Svensson, MD¹; Pär-Ola Bendahl, PhD²; Sara Alkner, MD, PhD³; Emma Hansson, MD, PhD^{4,5}; Lisa
- Rydén, MD, PhD^{1,6}; Looket Dihge, MD, PhD^{1,7*} 6
- 7 ¹Department of Clinical Sciences, Division of Surgery, Lund University, Lund, Sweden.
- 8 ²Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.
- 9 ³Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
- 10 ⁴Department of Plastic Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 11 ⁵Region Västra Götaland, Sahlgrenska University Hospital, Department of Plastic Surgery, Gothenborg Sweden.
- 12 ⁶Department of Surgery, Skåne University Hospital, Malmö, Sweden.
- 13 ⁷Department of Plastic and Reconstructive Surgery, Skåne University Hospital, Malmö, Sweden.
- 14

15 * Corresponding Author:

- 16 Looket Dihge,
- 17 Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Surgery, Medicon Village, SE-
- 18 223 81, Lund, Sweden
- 19 Email: looket.dihge@med.lu.se Tel: +46 702556835
- 20
- 21 Funding: This study was funded by The Governmental Funding of Clinical Research within the
- National Health Service (ALF), Swedish Research Council, Erling Persson Foundation, and Per-Eric 22 and Ulla Schyberg's Foundation. The funding sources had no role in the study design, analyses, data 23
- 24 interpretation, writing of the manuscript, or the decision to submit the manuscript.
- 26 **Data Availability Statement:** The data sets generated and analyzed in the present study are
- 27 available from the corresponding author upon reasonable request.
- 28

- 29 Disclosure: The authors have no conflicts of interest to declare.
- 30
- Key Words: Breast Neoplasms; Sentinel Lymph Node; Radiotherapy; Breast Reconstruction; 31
- 32 Nomograms; Clinical decision support.

2

33 Abstract

Background: Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstruction (IBR) in patients with breast cancer, and the sentinel lymph node (SLN) status is crucial in evaluating the need for PMRT. This study aimed to develop models to preoperatively predict the risk for SLN metastasis indicating the need for PMRT.

Methods: Women diagnosed with clinically node-negative (cN0) T1-T2 breast cancer from 38 January 2014 to December 2017 were identified within the Swedish National Quality Register 39 for Breast Cancer. Nomograms for nodal prediction based on preoperatively accessible patient 40 41 and tumor characteristics were developed using adaptive LASSO logistic regression. The prediction of ≥ 1 and >2 SLN macrometastases (macro-SLNMs) adheres to the current 42 guidelines on use of PMRT and reflects the exclusion criteria in ongoing clinical trials aiming 43 44 to de-escalate locoregional radiotherapy in patients with 1-2 macro-SLNMs, respectively. Predictive performance was evaluated using area under the receiver operating characteristic 45 curve (AUC) and calibration plots. 46

Results: Overall, 18 185 women were grouped into training (n = 13 656) and validation (n = 4529) cohorts. The well-calibrated nomograms predicting ≥ 1 and ≥ 2 macro-SLNMs displayed AUCs of 0.708 and 0.740, respectively, upon validation. By using the nomogram for ≥ 1 macro-SLNMs, the risk could be updated from the pre-test population prevalence 13% to the post-test range 2%-75%.

Conclusion: Nomograms based on routine patient and tumor characteristics could be used for
prediction of SLN status that would indicate PMRT need and assist the decision-making on
IBR for patients with cN0 breast cancer.

3

55 Introduction

Breast reconstructive surgery improves the quality of life of patients with breast cancer 56 undergoing mastectomy^{1, 2}. According to international guidelines, all patients undergoing 57 58 mastectomy should be counseled about reconstructive options. To evaluate the optimal timing and type of breast reconstruction, risk factors for postoperative complications must be 59 considered, such as smoking³, obesity⁴, and diabetes⁵. Specifically, postmastectomy 60 61 radiotherapy (PMRT) is recognized to impact outcomes in those receiving immediate breast reconstruction (IBR)⁶⁻¹⁰. Common complications involve capsular contracture and loss of 62 implant following immediate implant-based reconstructions^{6, 7}, while tissue necrosis is a 63 common complication associated with immediate autologous reconstructions and PMRT¹¹. 64 Therefore, evaluation of the need for PMRT is essential to support patients with breast cancer 65 and health-care providers in making informed decisions on breast reconstructive surgery and 66 IBR in particular. 67

The decision on PMRT is based on axillary lymph node metastasis, tumor size of >50 68 mm or involved resection margins¹²⁻¹⁴. Sentinel lymph node biopsy (SLNB) is the gold standard 69 70 for axillary nodal staging in patients with clinically node-negative (cN0) invasive breast cancer, and all patients with ≥ 1 SLN macrometastases (macro-SLNMs) (>2.0 mm) receive PMRT, 71 according to current guidelines¹²⁻¹⁴. Ongoing randomized clinical trials are examining the 72 possibility of omitting locoregional radiotherapy in patients with 1-2 macro-SLNMs¹⁵⁻¹⁷. 73 However, for those with a heavy nodal disease burden, PMRT remains advisable. 74 Consequently, the identification of patients with >2 macro-SLNMs is crucial. A non-invasive 75 tool for predicting SLN status could be beneficial in preoperatively identifying patients at risk 76 77 of postoperative complications associated with the requirement for PMRT following IBR. Although there are several nomograms for predicting axillary node status¹⁸⁻²⁰, most of them 78 include variables that are not routinely available in a preoperative setting. Moreover, predictive 79

4

tools to identify patients with cN0 breast cancer at high risk of macro-SLNM indicating the
need for PMRT, are still lacking.

This study aims to develop and validate nomograms for risk stratification of SLN 82 metastasis indicating the need for PMRT in patients with cN0 breast cancer using only routine 83 clinical patient and tumor characteristics. The primary endpoint is the prediction of ≥ 1 macro-84 SLNMs, according to current guidelines on the use of PMRT. The secondary endpoint is the 85 prediction of >2 macro-SLNMs that adhere to the exclusion criteria of ongoing randomized 86 controlled trials aiming to de-escalate the use of locoregional radiotherapy in patients with low 87 nodal metastatic burden. Adaptive LASSO logistic regression is used to minimize the risk of 88 overfitting the models. To our knowledge, this is the first study to present nomograms that 89 90 stratify the risk for SLNM, indicating the need for PMRT in patients with cN0 breast cancer.

91 Methods

92 *Study population*

93 This retrospective study was conducted using data from the Swedish National Quality Register for Breast Cancer (NKBC), a prospectively maintained, population-based register with 94 almost 100% completeness when cross-linked to the Swedish Cancer Register²¹. All women 95 diagnosed with invasive breast cancer in Sweden from January 2014 to December 2017, 96 primarily treated with surgery, were identified. The exclusion criteria were: bilateral breast 97 cancer, neoadjuvant chemotherapy, ductal carcinoma in situ (DCIS), tumor size >50 mm or 98 unknown tumor size, stage IV breast cancer, palpable axillary lymphadenopathy, absent or 99 incongruent data on axillary nodal status and omission of SLNB. The dataset was split into a 100 101 training cohort and a validation cohort. The training cohort comprised patients diagnosed in 2014-2016, while the remaining patients constituted the temporal validation cohort. 102

5

For all included patients, SLNB was the primary axillary staging procedure for evaluation 103 of axillary nodal status, and nodal metastases were categorized into macrometastases if a 104 metastatic deposit >2.0 mm was displayed²². For the prediction of >2 macro-SLNMs, patients 105 with macrometastases in at least two sentinel nodes and with any additional lymph node 106 107 metastasis identified by SLNB or by completion axillary lymph node dissection, were included. This research was performed in accordance with the Declaration of Helsinki and followed 108 the STROBE and TRIPOD guidelines for reporting observational studies^{23, 24}. The study was 109 approved by the Swedish Ethical Review Authority (2019–02139). Written informed consent 110 for participation was not required for this register-based study in accordance with the national 111 112 legislation and institutional requirements. The study was registered in the ISRCTN database 113 (ISRCTN 14341750).

Clinicopathological predictors 114

Based on previous studies on variables associated with SLN status^{25, 26}, the following 115 candidate predictors were evaluated: age at diagnosis, tumor size, Nottingham histological 116 grade, histological type, estrogen receptor (ER) status, progesterone receptor (PR) status, 117 amplification of human epidermal growth factor receptor 2 (HER2), and multifocality. Patient 118 age has been reported to have a non-linear association with nodal status, with the lowest 119 prevalence of lymphatic involvement for those around 70 years²⁷. Therefore, patients were 120 categorized into the following age groups: $\leq 65, 66-75$ and >75 years. Multifocality was defined 121 as the presence of ≥ 2 foci of invasive breast cancer within the same breast separated by benign 122 tissue on the histological examination of the excised section²⁸, and tumor size was defined as 123 the greatest dimension of the largest invasive focus. For ER and PR status, >1% stained nuclei 124 by immunohistochemistry (IHC) were considered positive according to the definitions of the 125 European Society for Medical Oncology (ESMO)¹². To evaluate HER2 status, IHC and in situ 126 hybridization (ISH) were performed, and tumors with IHC 3+ scoring and/or positive ISH-test 127

6

were regarded as HER2-positive. The histological type was categorized into three groups:
invasive carcinoma of no special type (NST), invasive lobular carcinoma (ILC), and other
invasive carcinoma. Mixed types were excluded from the analyzes.

131 Statistical analysis

132 Univariable logistic regression analysis was used to explore the unadjusted associations between each candidate predictor and the two endpoints in the training cohort. Adaptive 133 LASSO logistic regression²⁹ was then applied to select the most important predictors. LASSO 134 135 regression is a commonly used machine learning technique for variable selection and model development, minimizing the risk of overfitting by forcing the absolute sizes of the regression 136 coefficients of the standardized predictors to be bounded by a penalty factor, λ . The adaptive 137 form of LASSO leads to even more parsimonious models than the standard LASSO^{30,31}. To 138 determine the optimal value of λ , we used 10-fold cross-validation in the training cohort. Cases 139 140 with missing values for ≥ 1 candidate predictors were removed from the analyses. Two nomograms for predicting ≥ 1 and > 2 macro-SLNMs, respectively, were developed based on 141 the results from the adaptive LASSO regression analyses. 142

To evaluate each nomogram's discriminatory ability, the area under the receiver operating 143 characteristic (ROC) curve (AUC) was calculated in the development and validation cohorts. 144 Model accuracy was assessed in the validation cohort using calibration plots (graphical) and 145 calibration slope and intercept (numerical). For comparison purposes, corresponding prediction 146 models based on backward stepwise regression with uniform bootstrap-based shrinkage³² were 147 148 developed and are provided in the supplementary section (Supplemental Methods). All analyses were performed using STATA (StataCorp. 2021. Stata Statistical Software: Release 17. 149 College Station, TX: StataCorp LLC). 150

7

151 **Results**

152 Patient and tumor characteristics

From January 2014 to December 2017, 23 256 breast cancer tumors, primarily treated 153 with surgery, were registered in NKBC (Fig. S1). The final study cohort consisted of 18 185 154 patients with breast cancer who met the eligibility criteria. Of these, 13 656 were diagnosed 155 between 2014 and 2016, constituting the training cohort, and 4529 were diagnosed in 2017, 156 157 constituting the temporal validation cohort. Patient and tumor characteristics of the training and validation cohorts were comparable (Table 1). Overall, 2409 patients (13%) displayed ≥ 1 158 159 macro-SLNMs, and 278 (2%) displayed >2 macro-SLNMs. The overall median age at diagnosis was 64 years, and the median tumor size was 15 mm. Most patients displayed unifocal, hormone 160 receptor-positive, HER2-negative, grade II carcinoma of NST. 161

162 Variable selection and prediction model development using adaptive logistic LASSO regression

The results from the univariable logistic regression analyses are presented in Table S1. 163 164 Only patients with complete information on all candidate predictors were included in the adaptive LASSO logistic regression analyses (n = 12 168, 89%). Patient and tumor 165 characteristics of those included in the analyses and those removed due to any missing value of 166 167 the candidate predictors are presented in Table S2. For prediction of ≥ 1 macro-SLNMs, the adaptive LASSO regression-based prediction model identified patient age, tumor size, 168 multifocality, histological type, histological grade, ER, PR, and HER2 status as predictors. 169 Tumor size emerged as the most important predictor, followed by multifocality (Fig. S2a and 170 171 S2b).

For the prediction of >2 macro-SLNMs, adaptive LASSO regression identified the following predictors: tumor size, histological grade, multifocality, patient age (>65 years *vs*.

8

≤65 years), and histological type (ILC *vs.* NST or others) (Fig. S2c and S2d). Tumor size was
also the strongest predictor in this model.

176 The regression coefficients from the two adaptive LASSO regression analyses are presented in Table 2. Penalization of the coefficients was applied to minimize the risk of 177 178 overfitting. Along with the estimated intercept, these coefficients constitute the function used for outcome prediction. A positive coefficient indicates that the variable increases the predicted 179 probability, and a negative coefficient indicates that the variable decreases the predicted 180 probability. The retained predictors and their corresponding regression coefficients in the two 181 supplementary prediction models based on backward stepwise regression with bootstrap 182 uniform shrinkage are presented in Supplemental Results and Table S3. 183

184 Nomogram development

The results from the adaptive LASSO logistic regression analyses were used to develop Nomograms I and II, predicting ≥ 1 and ≥ 2 macro-SLNMs, respectively (Fig. 1). The penalized regression coefficients were transformed into specific scores on scales ranging from 0 to 10. By summarizing all scores in one nomogram, the patient's total score can be applied to a separate scale to predict the presence of ≥ 1 macro-SLNMs and ≥ 2 macro-SLNMs, respectively.

190 *Prediction model performance*

The ROC curves and calibration plots illustrating the discriminatory ability and the accuracy of the two prediction models in the validation cohort are presented in Fig. 2. For Nomogram I, the AUC value was 0.720 (95% confidence interval CI, 0.707–0.733) in the training cohort and 0.708 (0.684–0.731) in the validation cohort, respectively. As illustrated by the calibration plot, the nomogram displayed good agreement between the predicted and observed prevalence of macro-SLNM in the validation cohort. The calibration slope and intercept were estimated to be 1.030 and -0.108, respectively. These estimates are close to the

9

optimal values, which are 1.000 and 0.000, respectively. When applying the nomogram to the
overall study cohort, the individually predicted probability of ≥1 macro-SLNMs ranged from
200 2% for some low-risk patients up to 75% for some high-risk patients (Fig. 3).

For Nomogram II, the AUC values in the training and validation cohorts were 0.775 201 202 (0.743–0.807) and 0.740 (0.682–0.799), respectively (Fig. 2b). Similarly, this nomogram was well-calibrated with close approximation between the observed prevalence and predicted 203 204 probability in the validation cohort (Fig. 2d), with a calibration slope and intercept of 0.984 and 0.200, respectively. The individually predicted probability of >2 macro-SLNMs ranged from 205 <1% to 21% in the overall study cohort, with a mean of 2%. AUC values and model calibration 206 207 for the two supplementary models based on logistic regression are presented in Supplemental 208 results and Fig. S3.

209 **Discussion**

210 This study presents nomograms based on routine clinical patient and tumor characteristics for preoperative risk stratification of macro-SLNM indicating the need for PMRT. The chosen 211 endpoints are according to the current guidelines on the use of PMRT and reflect ongoing 212 213 clinical trials aiming to de-escalate locoregional irradiation in patients with low nodal metastatic burden. The nomograms displayed good discriminative ability, were well-calibrated, 214 215 and could be used to increase or decrease the preoperative likelihood of macro-SLNM. For some high-risk patients, the estimated risk of ≥ 1 macro-SLNMs increased from the study 216 217 population prevalence of 13% to 75% when using Nomogram I, while for others, the estimated 218 risk decreased to 2%. This way, the nomograms can assist patients with breast cancer and health-care providers in making informed decisions regarding reconstructive surgery. 219

To evaluate nodal status indicating the need for PMRT before a decision on IBR, intraoperative SLN staging was previously performed using imprint cytology or frozen sections³³. However, besides being time-consuming, intraoperative evaluation of the SLN status

10

inevitably leaves the patient with some degree of preoperative uncertainty regarding the nodal 223 224 status and suitability of IBR. Additionally, it complicates surgical planning, impacting the required time in the operating theatre and the necessary intraoperative resources. Several studies 225 suggested a staged SLNB procedure prior to mastectomy when IBR is planned³⁴⁻³⁶. While 226 enabling a complete pathological evaluation of the SLN status before breast surgery, this 227 strategy comes with the drawback of a two-step surgical procedure, including increased risk for 228 infections, delay in definitive surgery, and increased arm morbidity and hospital costs^{37, 38}. 229 Moreover, the prevalence of lymphatic metastasis at the time of diagnosis is declining³⁹, and 230 the number of patients benefitting from an altered treatment plan due to surgically verified 231 macro-SLNM and the need for PMRT is limited⁴⁰. Therefore, a complementary, non-invasive 232 prediction tool would be beneficial to preoperatively identify patients for whom IBR is 233 associated with a high risk of postoperative complications due to nodal macrometastasis and 234 PMRT. Ultimately, evaluating the risk factors impairing the outcome of IBR, including the 235 need for PMRT, is essential to support breast cancer patients and healthcare providers to make 236 informed decisions on breast reconstructive options. 237

In this study, we present two nomograms for preoperative prediction of SLN status 238 indicating the need for PMRT based on routinely accessible clinicopathological characteristics. 239 240 The nomograms were well-calibrated and displayed AUC values of 0.708 and 0.740 in the temporal validation cohort. For the prediction of axillary nodal status in cN0 breast cancer, the 241 Memorial Sloan Kettering Cancer Center (MSKCC) nomogram¹⁸ is one of the most frequently 242 used, with an AUC of 0.754. However, this nomogram includes lymphovascular invasion, 243 which is difficult to obtain in a preoperative setting⁴¹. Similar to most other nomograms for the 244 prediction of axillary nodal status, it does not consider the size of the metastatic deposit. 245 Previous trials have failed to prove any benefit of PMRT for patients with only micrometastatic 246 deposit ($\leq 2.0 \text{ mm}$)^{42, 43} and micrometastatic disease is not included in the current guidelines 247

11

concerning recommendations for PMRT¹²⁻¹⁴. Therefore, the presented Nomogram I was 248 249 developed to predict >1 macro-SLNMs specifically. The endpoint of the second nomogram was chosen to adhere to the protocols of ongoing randomized clinical trials questioning the benefit 250 of locoregional radiotherapy for patients with low nodal metastatic burden and verified 1-2 251 macro-SLNMs. In the POSNOC trial¹⁶, women with T1-T2 tumors and 1-2 macro-SLNMs are 252 randomized to no further axillary treatment vs. regional radiotherapy/axillary dissection. 253 Similarly, the MA.39¹⁷ and the T-REX¹⁵ trials investigate the need for regional lymph node 254 radiotherapy in patients with 1-2 macro-SLNMs; however, these trials are limited to patients 255 with ER-positive, HER2-negative breast cancer. Since radiotherapy is associated with an 256 increased risk of arm lymphedema⁴⁴, postmastectomy pain syndrome⁴⁵, and cardiopulmonary 257 disease^{46, 47}, a de-escalation of locoregional radiotherapy would not only improve the outcomes 258 of IBR but also reduce morbidity and non-breast cancer mortality for these patients. Clinical 259 260 guidelines concerning recommendations for PMRT will need to be revised if the omission of locoregional radiotherapy proves to be non-inferior in these patients, and the importance of 261 identifying metastasis limited to 1-2 macro-SLNMs will be diminished. To our knowledge, the 262 presented Nomogram II is the first nomogram to predict >2 macro-SLNMs in patients with 263 264 breast cancer for whom PMRT will remain recommended.

265 Adaptive LASSO regression was used to develop the nomograms. Although the LASSO algorithm has proved to be advantageous in the development of prediction models^{48, 49}, the 266 adaptive LASSO regression-based nomograms presented in this study did not outperform the 267 268 prediction models based on backward stepwise regression with bootstrap uniform shrinkage presented in Supplementary material. Moreover, the different algorithms showed only small 269 differences in variable selection. This observation is most likely due to the restricted number of 270 candidate variables recognized as key predictors, and thus, the advantages offered by the 271 adaptive LASSO algorithm were limited. 272

12

This study has some limitations. Besides its retrospective nature, all data were obtained 273 274 from a quality register with incomplete data for some clinicopathological characteristics. However, NKBC is a national, population-based register with high completeness when cross-275 linked to the Swedish Cancer Register²¹, and good concordance when validated by re-extraction 276 from medical records⁵⁰. Moreover, although many patients were removed from the modeling 277 278 due to missing data on one or more of the candidate variables, the study still included a large 279 number of observations (n = 18 185). Furthermore, this study is limited by the imbalanced distribution of macro-SLNM and >2 macro-SLNMs in the overall study cohort. Nevertheless, 280 this is an important observation, highlighting the small number of patients benefitting from an 281 282 altered treatment planning due to pathologically verified macro-SLNM and the need for PMRT. A strength of this study is the temporal validation of the nomograms regarding both 283 discriminatory ability and model calibration. Although only variables that could be obtained in 284 285 a preoperative setting were included as predictors for nodal disease, the included tumor characteristics were based on the definitive pathology result. Core needle biopsy has been 286 shown to accurately evaluate the histological type and grade, hormone receptor status, and 287 HER2 receptor status⁴¹; however, the differences between pre-and postoperative values are to 288 be expected. Additionally, mammography may over- or underestimate the pathological tumor 289 size⁵¹ and the presence of multifocality⁵². The results should, therefore, be interpreted with 290 caution. To enable the clinical application of these nomograms, a prospective validation study 291 is necessary. Moreover, it must be noted that the nomogram does not consider other risk factors 292 293 for postoperative complications of breast reconstructive surgery, such as obesity, smoking, and diabetes. 294

In conclusion, this study presents nomograms based on routine clinical patient and tumor characteristics for preoperative risk stratification of SLN status indicating the need for PMRT, addressing both current guidelines on the use of PMRT and ongoing clinical trials aiming to

- de-escalate irradiation. The nomograms could be valuable in preoperatively evaluating the risks 298
- and benefits of IBR regarding the need for PMRT, thus supporting individualized decision-299
- making on breast reconstructive surgery. 300

14

301 Figure Legends

Figure 1. Nomograms predicting sentinel lymph node (SLN) status indicating the need for
postmastectomy radiotherapy (PMRT): (a) probability of ≥1 SLN macrometastases (macroSLNMs) according to current guidelines on use of PMRT; and (b) probability of >2 macroSLNMs according to endpoints of ongoing clinical trials aiming to de-escalate the use of
irradiation.

HER2, human epidermal growth factor receptor 2; *PR*, progesterone receptor; *ER*, estrogen
receptor; *ILC*, invasive lobular carcinoma; *NST*, ductal carcinoma of no special type.

Figure 2. Performance of the nomograms in the temporal validation cohort. Receiver operating characteristic (ROC) curves representing the discriminatory ability for (a) Nomogram I, predicting \geq 1 sentinel lymph node macrometastases (macro-SLNMs), and (b) Nomogram II, predicting >2 macro-SLNMs. The Calibration plots illustrating the agreement between the observed prevalence and the predicted probability of (c) \geq 1 macro-SLNMs and (d) >2 macro-SLNMs, respectively, show good calibration, i.e., the predictions are not systematically biased. *AUC*, area under the curve.

Figure 3. Individual predictions of ≥ 1 and >2 sentinel lymph node macrometastases (macro-SLNMs) when applying the nomograms to the overall study cohort. (a) For Nomogram I, the predicted probability of ≥ 1 macro-SLNMs ranged from 2% for some low-risk patients up to 75% for some high-risk patients. (b) Likewise, the predicted probability of >2macro-SLNMs ranged from <1% to 21% when applying Nomogram II to each patient in the overall study cohort.

15

TABLES 322

Table 1. Patient and tumor characteristics of the training and validation cohorts 323

Variable	All $n = 18 \ 185$	Training cohort $n = 13656$	Validation cohort n = 4529
Age (years), median (range)	64 (22-95)	64 (23-95)	65 (22-95)
Missing	0	0	0
Patient age, categories			
≤65 years	9686 (53)	7320 (53)	2366 (52)
66-75 years	6220 (34)	4626 (34)	1594 (35)
>75 years	2279 (13)	1710 (13)	569 (13)
Missing	0	0	0
Tumor size (mm), median (range)	15 (1-50)	15 (1-50)	15 (1-50)
Missing	0	0	0
Histological type			
NST	13 979 (79)	10 511 (79)	3468 (80)
ILC	2320 (13)	1779 (13)	541 (12)
Others	1315 (7)	977 (7)	338 (8)
Missing	571	389	182
Nottingham histological grade			
Ι	4068 (23)	3081 (23)	987 (22)
II	9447 (53)	7118 (53)	2329 (52)
III	4467 (25)	3298 (24)	1169 (26)
Missing	203	159	44
Multifocality			
Yes	2924 (16)	2167 (16)	757 (17)
No	15 229 (84)	11 463 (84)	3766 (83)
Missing	32	26	6
ER status			
Positive	16 068 (92)	12 032 (92)	1036 (91)
Negative	1432 (8)	1028 (8)	404 (9)
Missing	685	596	89
PR status			
Positive	14 637 (85)	10 988 (86)	3649 (83)
Negative	2596 (15)	1844 (14)	752 (17)
Missing	952	824	128
HER2 status			
Positive	2009 (11)	1497 (11)	512 (11)
Negative	15 917 (89)	11 939 (89)	3978 (89)
Missing	259	220	39
Ki67 (%), median (range)	20 (0-100)	20 (0-100)	20 (1-100)
Missing	131	98	33
≥1 macro-SLNMs			
Yes	2409 (13)	1852 (14)	557 (12)
No	15 776 (87)	11 804 (86)	3972 (88)
Missing	0	0	0
>2 macro-SLNMs			
Yes	278 (2)	203 (1)	75 (2)
No	17 907 (98)	13 453 (99)	4454 (98)
Missing	0	0	0

Values in parentheses are valid percentages of each column if not otherwise explained. The 324

325 percentage values are rounded, and the total percentage may therefore not be 100.

- NST, no special type; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, 326
- progesterone receptor; HER2, human epidermal growth factor receptor 2; macro-SLNMs, 327
- 328 sentinel lymph node macrometastases.

17

Table 2. Penalized regression coefficients for prediction of ≥ 1 and >2 sentinel lymph 329

330 node macrometastases (macro-SLNMs) identified by adaptive LASSO regression (n = 12

168) 331

Variable	Prediction of ≥1 macro-SLNMs Penalized coefficients	Prediction of >2 macro-SLNMs Penalized coefficients
Age (years)		
≤65	0 (reference)	
66-75	-0.276	
>75	-0.128	
Age (years) (>65 <i>vs</i> . ≤65)		-0.171
Tumor size (mm)	0.068	0.076
Histological type		
NST	0 (reference)	
ILC	-0.270	
Others	-0.658	
Histological type (ILC vs. NST or others)		0.070
Histological grade		
I	0 (reference)	0 (reference)
П	0.359	0.743
III	0.489	0.813
Multifocality (multifocal vs. unifocal)	0.643	0.489
ER status (pos vs. neg)	0.225	
PR status (pos vs. neg)	0.122	
HER2 status (pos vs. neg)	-0.078	
Constant	-3.669	-6.451

332 Binary coding was used for categorical variables with two levels and two binary so-called

dummy variables for categorical variables with three levels. 333

- NST, ductal carcinoma of no special type; ILC, invasive lobular carcinoma; ER, estrogen 334
- receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. 335

18

336 **REFERENCES**

- Dauplat J, Kwiatkowski F, Rouanet P, et al. Quality of life after mastectomy with or without
 immediate breast reconstruction. Br J Surg. 2017;104(9):1197-206.
- 2. Archangelo SCV, Sabino Neto M, Veiga DF, Garcia EB, Ferreira LM. Sexuality, depression
- and body image after breast reconstruction. Clinics (Sao Paulo). 2019;74:e883.
- 341 3. Padubidri AN, Yetman R, Browne E, et al. Complications of postmastectomy breast
- 342 reconstructions in smokers, ex-smokers, and nonsmokers. Plast Reconstr Surg.
- 343 2001;107(2):342-9; discussion 50-1.
- 4. Fischer JP, Nelson JA, Kovach SJ, Serletti JM, Wu LC, Kanchwala S. Impact of obesity on
- outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets.
- 346 J Am Coll Surg. 2013;217(4):656-64.
- 5. Mortada H, Alwadai A, Bamakhrama B, et al. The Impact of Diabetes Mellitus on Breast
- 348 Reconstruction Outcomes and Complications: A Systematic Literature Review and Meta-
- analysis. Aesthetic Plast Surg. 2023.
- Barry M, Kell MR. Radiotherapy and breast reconstruction: a meta-analysis. Breast Cancer
 Res Treat. 2011;127(1):15-22.
- 352 7. de Boniface J, Coudé Adam H, Frisell A, et al. Long-term outcomes of implant-based
- immediate breast reconstruction with and without radiotherapy: a population-based study. Br J
 Surg. 2022;109(11):1107-15.
- 3558.Jagsi R, Momoh AO, Qi J, et al. Impact of Radiotherapy on Complications and Patient-
- 356Reported Outcomes After Breast Reconstruction. J Natl Cancer Inst. 2018;110(2):157-65.
- Shumway DA, Momoh AO, Sabel MS, Jagsi R. Integration of Breast Reconstruction and
 Postmastectomy Radiotherapy. J Clin Oncol. 2020;38(20):2329-40.
- Heller DR, Zhuo H, Zhang Y, et al. Surgical Outcomes of Mastectomy with Immediate
 Autologous Reconstruction Followed by Radiation. Ann Surg Oncol. 2021;28(4):2169-79.

361	11.	Liew B, Southall C, Kanapathy M, Nikkhah D. Does post-mastectomy radiation therapy
362		worsen outcomes in immediate autologous breast flap reconstruction? A systematic review
363		and meta-analysis. J Plast Reconstr Aesthet Surg. 2021;74(12):3260-80.
364	12.	Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice
365		Guidelines for diagnosis, treatment and follow-up [†] . Ann Oncol. 2019;30(8):1194-220.
366	13.	Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical
367		Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(6):691-722.
368	14.	Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of
369		Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical
370		Oncology Focused Guideline Update. Pract Radiat Oncol. 2016;6(6):e219-e34.
371	15.	Alkner S, de Boniface J, Lundstedt D, et al. Protocol for the T-REX-trial: tailored regional
372		external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel
373		node macrometastases - an open, multicentre, randomised non-inferiority phase 3 trial. BMJ
374		Open. 2023;13(9):e075543.
375	16.	Goyal A, Mann GB, Fallowfield L, et al. POSNOC-POsitive Sentinel NOde: adjuvant therapy
376		alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised
377		controlled trial of axillary treatment in women with early-stage breast cancer who have
378		metastases in one or two sentinel nodes. BMJ Open. 2021;11(12):e054365.
379	17.	Parulekar WR, Berrang T, Kong I, et al. Cctg MA.39 tailor RT: A randomized trial of regional
380		radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). Journal of
381		Clinical Oncology. 2019;37(15_suppl):TPS602-TPS.
382	18.	Bevilacqua JL, Kattan MW, Fey JV, Cody HS, 3rd, Borgen PI, Van Zee KJ. Doctor, what are
383		my chances of having a positive sentinel node? A validated nomogram for risk estimation. J
384		Clin Oncol. 2007;25(24):3670-9.
385	19.	Meretoja TJ, Heikkilä PS, Mansfield AS, et al. A predictive tool to estimate the risk of axillary
386		metastases in breast cancer patients with negative axillary ultrasound. Ann Surg Oncol.
387		2014;21(7):2229-36.

20.

Geng SK, Fu SM, Zhang HW, Fu YP. Predictive nomogram based on serum tumor markers

and clinicopathological features for stratifying lymph node metastasis in breast cancer. BMC

390		Cancer. 2022;22(1):1328.
391	21.	Swedish National Quality Registry for Breast Cancer 2021 [cited 19 Jan 2023]. Available
392		from: https://cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/.
393	22.	Edge S. AJCC Cancer Staging Manual, Eight Edition. New York: Springer; 2017.
394	23.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
395		Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement:
396		guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-9.
397	24.	Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable
398		prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement.
399		Br J Surg. 2015;102(3):148-58.
400	25.	Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in
401		4351 patients with invasive breast carcinoma treated in a single institution. Cancer.
402		2005;103(3):492-500.
403	26.	Farley C, Bassett R, Meric-Bernstam F, et al. To Dissect or Not to Dissect: Can We Predict
404		the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women
405		with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023;30(13):8327-34.
406	27.	Wildiers H, Van Calster B, van de Poll-Franse LV, et al. Relationship between age and
407		axillary lymph node involvement in women with breast cancer. J Clin Oncol.
408		2009;27(18):2931-7.
409	28.	Hartman J, Ehinger A, Kovács A, et al. [Kvalitetsbilaga för Bröstpatologi (KVAST)] 2022
410		[cited 5 Apr 2023]. Available from:
411		https://kunskapsbanken.cancercentrum.se/diagnoser/brostcancer/vardprogram/kvalitetsdokum
412		ent-forpatologi/#chapterForfattare-KVAST-gruppen-for-brostpatologi.
413	29.	Shortreed SM, Ertefaie A. Outcome-adaptive lasso: Variable selection for causal inference.
414		Biometrics. 2017;73(4):1111-22.

415	30.	Tibshirani R. Regression Shrinkage and Selection via the Lasso. Journal of the Royal
416		Statistical Society Series B (Methodological). 1996;58(1):267-88.
417	31.	Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med.
418		1997;16(4):385-95.
419	32.	Fernandez-Felix BM, García-Esquinas E, Muriel A, Royuela A, Zamora J. Bootstrap internal
420		validation command for predictive logistic regression models. The Stata Journal.
421		2021;21(2):498-509.
422	33.	Wood BC, Levine EA, Marks MW, David LR. Outcomes of immediate breast reconstruction
423		in patients undergoing single-stage sentinel lymph node biopsy and mastectomy. Ann Plast
424		Surg. 2011;66(5):564-7.
425	34.	Teven C, Agarwal S, Jaskowiak N, et al. Pre-mastectomy sentinel lymph node biopsy: a
426		strategy to enhance outcomes in immediate breast reconstruction. Breast J. 2013;19(5):496-
427		503.
428	35.	McGuire K, Rosenberg AL, Showalter S, Brill KL, Copit S. Timing of sentinel lymph node
429		biopsy and reconstruction for patients undergoing mastectomy. Ann Plast Surg.
430		2007;59(4):359-63.
431	36.	Klauber-Demore N, Calvo BF, Hultman CS, et al. Staged sentinel lymph node biopsy before
432		mastectomy facilitates surgical planning for breast cancer patients. Am J Surg.
433		2005;190(4):595-7.
434	37.	Husen M, Paaschburg B, Flyger HL. Two-step axillary operation increases risk of arm
435		morbidity in breast cancer patients. Breast. 2006;15(5):620-8.
436	38.	Rönkä R, Smitten K, Sintonen H, et al. The impact of sentinel node biopsy and axillary
437		staging strategy on hospital costs. Ann Oncol. 2004;15(1):88-94.
438	39.	Tabar L, Chen TH, Yen AM, et al. Effect of Mammography Screening on Mortality by
439		Histological Grade. Cancer Epidemiol Biomarkers Prev. 2018;27(2):154-7.
440	40.	Svensson M, Dihge L. The Role of Surgical Axillary Staging Prior to Immediate Breast
441		Reconstruction in the Era of De-Escalation of Axillary Management in Early Breast Cancer. J
442		Pers Med. 2022;12(8).

443	41.	Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast
444		cancer needle core biopsy specimens. J Clin Pathol. 2007;60(12):1300-6.
445	42.	Luo H, Yang OO, He JL, Lan T. Impact of Post-Mastectomy Radiation Therapy for Sentinel
446		Lymph Node Micrometastases in Early-Stage Breast Cancer Patients. Med Sci Monit.
447		2022;28:e933275.
448	43.	Mamtani A, Patil S, Stempel M, Morrow M. Axillary Micrometastases and Isolated Tumor
449		Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast
450		Cancer. Ann Surg Oncol. 2017;24(8):2182-8.
451	44.	Konishi T, Tanabe M, Michihata N, et al. Risk factors for arm lymphedema following breast
452		cancer surgery: a Japanese nationwide database study of 84,022 patients. Breast Cancer.
453		2023;30(1):36-45.
454	45.	Ren Y, Kong X, Yang Q, et al. Incidence, risk factors, prevention and treatment of
455		postmastectomy pain syndrome in breast cancer: A multicenter study. Int J Surg.
456		2022;106:106937.
457	46.	Taylor C, Correa C, Duane FK, et al. Estimating the Risks of Breast Cancer Radiotherapy:
458		Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous
459		Randomized Trials. J Clin Oncol. 2017;35(15):1641-9.
460	47.	Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after
461		radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-98.
462	48.	Su YR, Buist DS, Lee JM, et al. Performance of statistical and machine learning risk
463		prediction models for surveillance benefits and failures in breast cancer survivors. Cancer
464		Epidemiol Biomarkers Prev. 2023.
465	49.	Huang X, Xu X, Xu A, et al. Exploring the most appropriate lymph node staging system for
466		node-positive breast cancer patients and constructing corresponding survival nomograms. J
467		Cancer Res Clin Oncol. 2023.
468	50.	Löfgren L, Eloranta S, Krawiec K, Asterkvist A, Lönnqvist C, Sandelin K. Validation of data
469		quality in the Swedish National Register for Breast Cancer. BMC Public Health.
470		2019;19(1):495.

- 471 51. Gruber IV, Rueckert M, Kagan KO, et al. Measurement of tumour size with mammography,
- 472 sonography and magnetic resonance imaging as compared to histological tumour size in
- 473 primary breast cancer. BMC Cancer. 2013;13:328.
- 474 52. Steinhof-Radwańska K, Lorek A, Holecki M, et al. Multifocality and Multicentrality in Breast
- 475 Cancer: Comparison of the Efficiency of Mammography, Contrast-Enhanced Spectral
- 476 Mammography, and Magnetic Resonance Imaging in a Group of Patients with Primarily
- 477 Operable Breast Cancer. Curr Oncol. 2021;28(5):4016-30.



(b)

(a)

Nomogram II Prediction of >2 macro–SLNMs













0.20